Podcasts about Lymph node

Ever wondered why you still have inflammation and pain when you are working your lymphatic system? I mean it's supposed to help you feel better right? Well that all depends on how you are working your lymphatic system because not lymph reset programs are the same. You have to dive deep and look at the biggest blocks in the central lymphatics. If you miss the Central lyphatics you are still going to struggle. You cannot reach those by dry brushing alone. Take a listen. Learn. Share. Enjoy. Change your life. And don't forget to watch the video version on our YouTube channel. Stop Chasing Pain on YOUTUBE. 

Vincent and Cindy discuss differences between MPox-specific T cell responses following infection and vaccination, and lymph node macrophage control of memory B cell localization and trafficking that might be important for choosing which arm to get a vaccine. Hosts: Vincent Racaniello and Cindy Leifer Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Different T memory response to MPox infection or vaccination (Nat Comm 2025) Macrophages direct B cell recall responses after vaccination (Cell 2025) Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.

To have your question featured in a future video, please email: questions@morses.tv Please include at least: Age, Weight and as much history as possible.

Dr. Ko Un “Clara” Park and Dr. Mylin Torres present the latest evidence-based changes to the SLNB in early-stage breast cancer guideline. They discuss the practice-changing trials that led to the updated recommendations and topics such as when SLNB can be omitted, when ALND is indicated, radiation and systemic treatment decisions after SLNB omission, and the role of SLNB in special circumstances. We discuss the importance of shared decision-making and other ongoing and future de-escalation trials that will expand knowledge in this space. Read the full guideline update, “Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update” at www.asco.org/breast-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/breast-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-00099       Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Ko Un "Clara" Park from Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Dr. Mylin Torres from Glenn Family Breast Center at Winship Cancer Institute of Emory University, co-chairs on “Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update.” Thank you for being here today, Dr. Park and Dr. Torres. Dr. Mylin Torres: Thank you, it's a pleasure to be here. Brittany Harvey: And before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Torres and Dr. Park, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. To start us off, Dr. Torres, what is the scope and purpose of this guideline update on the use of sentinel lymph node biopsy in early-stage breast cancer? Dr. Mylin Torres: The update includes recommendations incorporating findings from trials released since our last published guideline in 2017. It includes data from nine randomized trials comparing sentinel lymph node biopsy alone versus sentinel lymph node biopsy with a completion axillary lymph node dissection. And notably, and probably the primary reason for motivating this update, are two trials comparing sentinel lymph node biopsy with no axillary surgery, all of which were published from 2016 to 2024. We believe these latter two trials are practice changing and are important for our community to know about so that it can be implemented and essentially represent a change in treatment paradigms. Brittany Harvey: It's great to hear about these practice changing trials and how that will impact these recommendation updates. So Dr. Park, I'd like to start by reviewing the key recommendations across all of these six overarching clinical questions that the guideline addressed. So first, are there patients where sentinel lymph node biopsy can be omitted? Dr. Ko Un "Clara" Park: Yes. The key change in the current management of early-stage breast cancer is the inclusion of omission of sentinel lymph node biopsy in patients with small, less than 2 cm breast cancer and a negative finding on preoperative axillary ultrasound. The patients who are eligible for omission of sentinel lymph node biopsy according to the SOUND and INSEMA trial are patients with invasive ductal carcinoma that is size smaller than 2 cm, Nottingham grades 1 and 2, hormone receptor-positive, HER2-negative in patients intending to receive adjuvant endocrine therapy, and no suspicious lymph nodes on axillary ultrasound or if they have only one suspicious lymph node, then the biopsy of that lymph node is benign and concordant according to the axillary ultrasound findings. The patients who are eligible for sentinel lymph node biopsy omission according to the SOUND and INSEMA trials were patients who are undergoing lumpectomy followed by whole breast radiation, especially in patients who are younger than 65 years of age. For patients who are 65 years or older, they also qualify for omission of sentinel lymph node biopsy in addition to consideration for radiation therapy omission according to the PRIME II and CALGB 9343 clinical trials. And so in those patients, a more shared decision-making approach with the radiation oncologist is encouraged. Brittany Harvey: Understood. I appreciate you outlining that criteria for when sentinel lymph node biopsy can be omitted and when shared decision making is appropriate as well. So then, Dr. Torres, in those patients where sentinel lymph node biopsy is omitted, how are radiation and systemic treatment decisions impacted? Dr. Mylin Torres: Thank you for that question. I think there will be a lot of consternation brought up as far as sentinel lymph node biopsy and the value it could provide in terms of knowing whether that lymph node is involved or not. But as stated, sentinel lymph node biopsy actually can be safely omitted in patients with low risk disease and therefore the reason we state this is that in both SOUND and INSEMA trial, 85% of patients who had a preoperative axillary ultrasound that did not show any signs of a suspicious lymph node also had no lymph nodes involved at the time of sentinel node biopsy. So 85% of the time the preoperative ultrasound is correct. So given the number of patients where preoperative ultrasound predicts for no sentinel node involvement, we have stated within the guideline that radiation and systemic treatment decisions should not be altered in the select patients with low risk disease where sentinel lymph node biopsy can be omitted. Those are the patients who are postmenopausal and age 50 or older who have negative findings on preoperative ultrasound with grade 1 or 2 disease, small tumors less than or equal to 2 cm, hormone receptor-positive, HER2-negative breast cancer who undergo breast conserving therapy. Now, it's important to note in both the INSEMA and SOUND trials, the vast majority of patients received whole breast radiation. In fact, within the INSEMA trial, partial breast irradiation was not allowed. The SOUND trial did allow partial breast irradiation, but in that study, 80% of patients still received whole breast treatment. Therefore, the preponderance of data does support whole breast irradiation when you go strictly by the way the SOUND and INSEMA trials were conducted. Notably, however, most of the patients in these studies had node-negative disease and had low risk features to their primary tumors and would have been eligible for partial breast irradiation by the ASTRO Guidelines for partial breast treatment. So, given the fact that 85% of patients will have node-negative disease after a preoperative ultrasound, essentially what we're saying is that partial breast irradiation may be offered in these patients where omission of sentinel node biopsy is felt to be safe, which is in these low risk patients. Additionally, regional nodal irradiation is something that is not indicated in the vast majority of patients where omission of sentinel lymph node biopsy is prescribed and recommended, and that is because very few of these patients will actually end up having pathologic N2 disease, which is four or more positive lymph nodes. If you look at the numbers from both the INSEMA and the SOUND trial, the number of patients with pathologic N2 disease who did have their axilla surgically staged, it was less than 1% in both trials. So, in these patients, regional nodal irradiation, there would be no clear indication for that more aggressive and more extensive radiation treatment. The same principles apply to systemic therapy. As the vast majority of these patients are going to have node-negative disease with a low risk primary tumor, we know that postmenopausal women, even if they're found to have one to three positive lymph nodes, a lot of the systemic cytotoxic chemotherapy decisions are driven by genomic assay score which is taken from the primary tumor. And therefore nodal information in patients who have N1 disease may not be gained in patients where omission of sentinel lymph node biopsy is indicated in these low risk patients. 14% of patients have 1 to 3 positive lymph nodes in the SOUND trial and that number is about 15% in the INSEMA trial. Really only the clinically actionable information to be gained is if a patient has four or more lymph nodes or N2 disease in this low risk patient population. So, essentially when that occurs it's less than 1% of the time in these patients with very favorable primary tumors. And therefore we thought it was acceptable to stand by a recommendation of not altering systemic therapy or radiation recommendations based on omission of sentinel nodes because the likelihood of having four more lymph nodes is so low. Dr. Ko Un "Clara" Park: I think one thing to add is the use of CDK4/6 inhibitors to that and when we look at the NATALEE criteria for ribociclib in particular, where node-negative patients were included, the bulk majority of the patients who were actually represented in the NATALEE study were stage III disease. And for stage I disease to upstage into anatomic stage III, that patient would need to have pathologic N2 disease. And as Dr. Torres stated, the rate of having pathologic N2 disease in both SOUND and INSEMA studies were less than 1%. And therefore it would be highly unlikely that these patients would be eligible just based on tumor size and characteristics for ribociclib. So we think that it is still safe to omit sentinel lymph node biopsy and they would not miss out, if you will, on the opportunity for CDK4/6 inhibitors. Brittany Harvey: Absolutely. I appreciate you describing those recommendations and then also the nuances of the evidence that's underpinning those recommendations, I think that's important for listeners. So Dr. Park, the next clinical question addresses patients with clinically node negative early stage breast cancer who have 1 or 2 sentinel lymph node metastases and who will receive breast conserving surgery with whole breast radiation therapy. For these patients, is axillary lymph node dissection needed? Dr. Ko Un "Clara" Park: No. And this is confirmed based on the ACOSOG Z0011 study that demonstrated in patients with 1 to 3 positive sentinel lymph node biopsy when the study compared completion axillary lymph node dissection to no completion axillary lymph node dissection, there was no difference. And actually, the 10-year overall survival as reported out in 2017 and at a median follow up of 9.3 years, the overall survival again for patients treated with sentinel lymph node biopsy alone versus those who were treated with axillary lymph node dissection was no different. It was 86.3% in sentinel lymph node biopsy versus 83.6% and the p-value was non-inferior at 0.02. And so we believe that it is safe for the select patients who are early stage with 1 to 2 positive lymph nodes on sentinel lymph node biopsy, undergoing whole breast radiation therapy to omit completion of axillary lymph node dissection. Brittany Harvey: Great, I appreciate you detailing what's recommended there as well. So then, to continue our discussion of axillary lymph node dissection, Dr. Torres, for patients with nodal metastases who will undergo mastectomy, is axillary lymph node dissection indicated? Dr. Mylin Torres: It's actually not and this is confirmed by two trials, the AMAROS study as well as the SENOMAC trial. And in both studies, they compared a full lymph node dissection versus sentinel lymph node biopsy alone in patients who are found to have 1 to 2 positive lymph nodes and confirmed that there was no difference in axillary recurrence rates, overall survival or disease-free survival. What was shown is that with more aggressive surgery completion axillary lymph node dissection, there were higher rates of morbidity including lymphedema, shoulder pain and paresthesias and arm numbness, decreased functioning of the arm and so there was only downside to doing a full lymph node dissection. Importantly, in both trials, if a full lymph node dissection was not done in the arm that where sentinel lymph node biopsy was done alone, all patients were prescribed post mastectomy radiation and regional nodal treatment and therefore both studies currently support the use of post mastectomy radiation and regional nodal treatment when a full lymph node dissection is not performed in these patients who are found to have N1 disease after a sentinel node biopsy. Brittany Harvey: Thank you. And then Dr. Park, for patients with early-stage breast cancer who do not have nodal metastases, can completion axillary lymph node dissection be omitted? Dr. Ko Un "Clara" Park: Yes, and this is an unchanged recommendation from the earlier ASCO Guidelines from 2017 as well as the 2021 joint guideline with Ontario Health, wherein patients with clinically node-negative early stage breast cancer, the staging of the axilla can be performed through sentinel lymph nodal biopsy and not completion axillary lymph node dissection. Brittany Harvey: Understood. So then, to wrap us up on the clinical questions here, Dr. Park, what is recommended regarding sentinel lymph node biopsy in special circumstances in populations? Dr. Ko Un "Clara" Park: One key highlight of the special populations is the use of sentinel lymph node biopsy for evaluation of the axilla in clinically node negative multicentric tumors. While there are no randomized clinical trials evaluating specifically the role of sentinel lymph nodal biopsy in multicentric tumors, in the guideline, we highlight this as one of the safe options for staging of the axilla and also for pregnant patients, these special circumstances, it is safe to perform sentinel lymph node biopsy in pregnant patients with the use of technetium - blue dye should be avoided in this population. In particular, I want to highlight where sentinel lymph node biopsy should not be used for staging of the axilla and that is in the population with inflammatory breast cancer. There are currently no studies demonstrating that sentinel lymph node biopsy is oncologically safe or accurate in patients with inflammatory breast cancer. And so, unfortunately, in this population, even after neoadjuvant systemic therapy, if they have a great response, the current guideline recommends mastectomy with axillary lymph node dissection. Brittany Harvey: Absolutely. I appreciate your viewing both where sentinel lymph node can be offered in these special circumstances in populations and where it really should not be used. So then, Dr. Torres, you talked at the beginning about how there's been these new practice changing trials that really impacted these recommendations. So in your view, what is the importance of this guideline update and how does it impact both clinicians and patients? Dr. Mylin Torres: Thank you for that question. This update and these trials that inform the update represent a significant shift in the treatment paradigm and standard of care for breast cancer patients with early-stage breast cancer. When you think about it, it seems almost counterintuitive that physicians and patients would not want to know if a lymph node is involved with cancer or not through sentinel lymph node biopsy procedure. But what these studies show is that preoperative axillary ultrasound, 85% of the time when it's negative, will correctly predict whether a sentinel lymph node is involved with cancer or not and will also be negative. So if you have imaging that's negative, your surgery is likely going to be negative. Some people might ask, what's the harm in doing a sentinel lymph node biopsy? It's important to recognize that upwards of 10% of patients, even after sentinel lymph node biopsy will develop lymphedema, chronic arm pain, shoulder immobility and arm immobility. And these can have a profound impact on quality of life. And if there is not a significant benefit to assessing lymph nodes, particularly in someone who has a preoperative axillary ultrasound that's negative, then why put a patient at risk for these morbidities that can impact them lifelong? Ideally, the adoption of omission of sentinel lymph node biopsy will lead to more multidisciplinary discussion and collaboration in the preoperative setting especially with our diagnostic physicians, radiology to assure that these patients are getting an axillary ultrasound and determine how omission of sentinel lymph node biopsy may impact the downstream treatments after surgery, particularly radiation and systemic therapy decisions, and will be adopted in real world patients, and how clinically we can develop a workflow where together we can make the best decisions for our patients in collaboration with them through shared decision making. Brittany Harvey: Absolutely. It's great to have these evidence-based updates for clinicians and patients to review and refer back to. So then finally, Dr. Park, looking to the future, what are the outstanding questions and ongoing trials regarding sentinel lymph node biopsy in early-stage breast cancer? Dr. Ko Un "Clara" Park: I think to toggle on Dr. Torres's comment about shared decision making, the emphasis on that I think will become even more evident in the future as we incorporate different types of de-escalation clinical studies. In particular, because as you saw in the SOUND and INSEMA studies, when we de-escalate one modality of the multimodality therapy, i.e., surgery, the other modalities such as radiation therapy and systemic therapy were “controlled” where we were not de-escalating multiple different modalities. However, as the audience may be familiar with, there are other types of de-escalation studies in particular radiation therapy, partial breast irradiation or omission of radiation therapy, and in those studies, the surgery is now controlled where oftentimes the patients are undergoing surgical axillary staging. And conversely when we're looking at endocrine therapy versus radiation therapy clinical trials, in those studies also the majority of the patients are undergoing surgical axillary staging. And so now as those studies demonstrate the oncologic safety of omission of a particular therapy, we will be in a position of more balancing of the data of trying to select which patients are the safe patients for omission of certain types of modality, and how do we balance whether it's surgery, radiation therapy, systemic therapy, endocrine therapy. And that's where as Dr. Torres stated, the shared decision making will become critically important. I'm a surgeon and so as a surgeon, I get to see the patients oftentimes first, especially when they have early-stage breast cancer. And so I could I guess be “selfish” and just do whatever I think is correct. But whatever the surgeon does, the decision does have consequences in the downstream decision making. And so the field really needs to, as Dr. Torres stated earlier, rethink the workflow of how early-stage breast cancer patients are brought forth and managed as a multidisciplinary team. I also think in future studies the expansion of the data to larger tumors, T3, in particular,reater than 5 cm and also how do we incorporate omission in that population will become more evident as we learn more about the oncologic safety of omitting sentinel lymph node biopsy. Dr. Mylin Torres: In addition, there are other outstanding ongoing clinical trials that are accruing patients right now. They include the BOOG 2013-08 study, SOAPET, NAUTILUS and the VENUS trials, all looking at patients with clinical T1, T2N0 disease and whether omission of sentinel lymph node biopsy is safe with various endpoints including regional recurrence, invasive disease-free survival and distant disease-free survival. I expect in addition to these studies there will be more studies ongoing even looking at the omission of sentinel lymph node biopsy in the post-neoadjuvant chemotherapy setting. And as our imaging improves in the future, there will be more studies improving other imaging modalities, probably in addition to axillary ultrasound in an attempt to accurately characterize whether lymph nodes within axilla contain cancer or not, and in that context whether omission of sentinel lymph node biopsy even in patients with larger tumors post-neoadjuvant chemotherapy may be done safely and could eventually become another shift in our treatment paradigm. Brittany Harvey: Yes. The shared decision making is key as we think about these updates to improve quality of life and we'll await data from these ongoing trials to inform future updates to this guideline. So I want to thank you both so much for your extensive work to update this guideline and thank you for your time today. Dr. Park and Dr. Torres. Dr. Mylin Torres: Thank you. Dr. Ko Un "Clara" Park: Thank you. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/breast-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

In this episode Dr. Perry talks about the Cisterna Chyli the largest lymph node of the body located in the center of the abdomen. When that lymph node is stagnated you can get swelling inflammation discomfort or pain anywhere in the body. Come join us I learn how to help yourself heal. BIG 6 RESET LINK: https://www.stopchasingpain.com/the-big-6-tm/

Do you palpate for the epitrochlear lymph node?   Check out the papers mentioned Selby CD, Marcus HS, Toghill PJ. Enlarged epitrochlear lymph nodes: an old physical sign revisited. J R Coll Physicians Lond. 1992 Apr;26(2):159-61. PMID: 1588523; PMCID: PMC5375540. https://pmc.ncbi.nlm.nih.gov/articles/PMC5375540/    Catalano O, Nunziata A, Saturnino PP, Siani A. Epitrochlear lymph nodes: Anatomy, clinical aspects, and sonography features. Pictorial essay(). J Ultrasound. 2010 Dec;13(4):168-74. doi: 10.1016/j.jus.2010.10.010. Epub 2010 Nov 18. PMID: 23397026; PMCID: PMC3553226.  https://pmc.ncbi.nlm.nih.gov/articles/PMC3553226/    Pannu AK, Prakash G, Jandial A, Kopp CR, Kumari S. Epitrochlear lymphadenopathy. Korean J Intern Med. 2019 Nov;34(6):1396. doi: 10.3904/kjim.2018.218. Epub 2018 Dec 6. PMID: 30514055; PMCID: PMC6823563. https://pmc.ncbi.nlm.nih.gov/articles/PMC6823563/   Freeman AM, Matto P. Lymphadenopathy. [Updated 2023 Feb 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513250/        www.rnzcuc.org.nz podcast@rnzcuc.org.nz https://www.facebook.com/rnzcuc https://twitter.com/rnzcuc   Music licensed from www.premiumbeat.com Full Grip by Score Squad   This podcast is intended to assist in ongoing medical education and peer discussion for qualified health professionals.  Please ensure you work within your scope of practice at all times.  For personal medical advice always consult your usual doctor 

In this episode of Own Your Health, Katie Brindle answers your questions, including unique listener questions on how to safely perform facial Gua Sha after a double mastectomy and lymph node removal. Katie shares her expert advice on supporting lymphatic health and explains why brushing, tapping, and gentle Gua Sha techniques can make a huge difference in boosting energy and reducing sluggishness. Let us know if any of the techniques seen in this video have helped you. Don't forget to comment or write in and your questions can be featured in one of Katie's episodes! This episode is sponsored by Liminal, a brand transforming how we approach menopause. Founded by Rebekah Brown, Liminal empowers women with naturopathic, whole-food-led supplements designed to support your unique needs. Beyond products, they offer a supportive community, masterclasses, and real-time social groups to help women connect and thrive. Use KATIE20 for a 20% discount on single purchases within the Liminal range - https://liveliminal.com In addition, we are teaming up with The Naked Pharmacy, a registered pharmacy offering science-backed supplements and free health consultations with expert pharmacists. Whether you need support with menopause, gut health, weight management, or boosting energy and mood, they've got you covered! Don't miss out on 20% off with the code KATIE20 at thenakedpharmacy.com Watch the full episode on YouTube: https://www.youtube.com/@KatieBrindleOfficial/videos To contact Katie, email: ownyourhealth@katiebrindle.com Sign up to Katie's newsletter: https://www.katiebrindle.com/ Disclaimer: Techniques highlighted in this episode are designed to support your overall wellbeing and should not be used as a substitute for any medical treatment you may be undergoing. You should not use the information in this podcast for diagnosing or treating a health problem or disease. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Lymph nodes are little bean shaped structures filled with the cells of the immune system and dotted around the body. Pathogens from skin injuries or that enter the body in other ways are passed to a lymph node and the cells here can respond. They are major parts of the immune system but metastatic cancer cells may also pass here, get stuck and continue to proliferate. This is important anatomy then, so let's quickly talk about it in around 5 minutes of podcast world time.

August 23, 2024 Mark, Scott, and Ray talk about two questions that came into the PRS Communities:I have Optum requesting records on all of our clot evac cases where something in the bladder was fulgurated during the same session and after record review we fail the audit.Now compliance is very quick to say refund it, stop billing it, its bundled, etc.But we know a modifier is allowed so when is it allowed????Everything I find online like AAPC says to bill both 52214 and 52001-59 but there is nothing recent and nothing concrete about what is considered distinct. I mean using a clot evacuator is different than using a loop electrode. Below are the Optum rationales.So the urologist does a cysto on hematuria work up, and they wind up using an evacuator to remove huge amounts of clot burden. Then use a loop electrode to fulgurate some areas that look suspicious.Why is that service not considered distinct? Compliance says its incidental but they can't tell me when it wouldn't be incidental and I don't want to let optum take back money without an argument.Hi, I would like to ask a coding question please. Thank you so much!For Robot-assisted left partial nephrectomy and Resection of a left renal hilar lymph node, Do we code any additional CPT to capture renal hilar lymph node, in addition to partial nephrectomy 50543?Pathology report had a separate report for Renal hilar lymph node dissection, which was negative for carcinoma. And for partial nephrectomy, path showed Renal cell carcinoma. PRS Billing and Other Services - Book a Call with Mark Painter or Marianne DescioseClick Here to Get More Information and Request a QuoteUrology Advanced Coding and Reimbursement Seminars - In-Person SeminarsRegister Now for the Urology Advanced Coding and Reimbursement SeminarSpecial Early Bird code: 25UACRS732 Click Here for Information and RegistrationEvent DetailsLocation:Las Vegas: December 6-7, 2024, at HorseshoeNew Orleans: January 31-February 1, 2025, at Harrah'sTime: Friday 8 am - 4 pm, Saturday 8 am - 3:30 pmIncludes: Breakfast and Lunch on both days, plus 14 AAPC CEUs   The Thriving Urology Practice Facebook group.The Thriving Urology Practice Facebook Group link to join:https://www.facebook.com/groups/ThrivingPractice/    Join the discussion:Urology Coding and Reimbursement Group - Join for free and ask your questions, and share your wisdom.Click Here to Start Your Free Trial of AUACodingToday.com

Data analyst John Beaudoin returns with what he calls the “BIGGEST story” that everyone is missing about the pandemic, paradoxes in the graphing data, and evidence of an increase in lymph node cancer. Dr. Kelly Victory is filling in as host, joined by Beaudoin and CHD's Karl Jablonowski Ph.D. John Beaudoin, Sr. is an engineer and data analyst with a background in high-tech and military sales. He is the author of “The Real CdC: COVID Facts For Regular People” and “The CDC Memorandum”. Follow him at https://x.com/JohnBeaudoinSr and read more at https://TheRealCdC.com Karl Jablonowski Ph.D. is a specialist in Biomedical and Health Informatics. He has expertise in managing terabyte-sized databases, including biological and electronic medical record systems. Dr. Jablonowski's research contributions include over 14 peer-reviewed journal articles focused on data mining and analysis for scientific investigation. His work centers on leveraging large-scale data for advancements in health and biomedical sciences. 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at https://drdrew.com/sponsors  • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at https://drdrew.com/fatty15 • CAPSADYN - Get pain relief with the power of capsaicin from chili peppers – without the burning! Capsadyn's proprietary formulation for joint & muscle pain contains no NSAIDs, opioids, anesthetics, or steroids. Try it for 15% off at https://drdrew.com/capsadyn • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at https://drdrew.com/paleovalley • TRU NIAGEN - For almost a decade, Dr. Drew has been taking a healthy-aging supplement called Tru Niagen, which uses a patented form of Nicotinamide Riboside to boost NAD levels. Use code DREW for 20% off at https://drdrew.com/truniagen • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at https://twc.health/drew 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (https://kalebnation.com) and Susan Pinsky (https://twitter.com/firstladyoflove). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

A TEAM OF SCIENTISTS HAVE LAUNCHED THE FIRST HUMAN TRIAL IN AN ATTEMPT TO GROW A NEW LIVER INSIDE OF A HUMAN USING LYMPH NODES, WHICH COULD TRANSFORM ORGAN DONATION IF SUCCESSFUL. WE SPEAK WITH DR. MICHAEL HUFFORD, CEO OF LYGENESIS, A PITTSBURGH-BASED BIOTECH COMPANY BEHIND THE RESEARCH.

To have your question featured in a future video, please email: questions@drmdc.health

More great highlights from the latest edition of European Urology!! Here on the European Urology Podcast we bring you selected highlights each month with some great guests. As ever we highlight two key papers (details below) from this month's journal, including interviews with key authors and expert commentators. We also look at other highlights in this month's journal with guest contributor Dr Eduardo Felicia (Lisbon).  Even better on our Youtube channelPodcast Priority Papers1. Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men Featured author - Dr Ola Bratt (Gothenburg University, Sweden)Discussant - Dr Gianluca Giannarini (University Hospital, Udine, Italy)2. Management of Lymph Node–positive Penile Cancer: A Systematic Review Featured author - Dr Ashwin Sachdeva (The Christie NHS Foundation Trust, Manchester)Discussant - Dr Sarah Psutka (Fred Hutch Cancer Centre, Seattle)Full index to European Urology March 2024 

In this episode of the PRS Global Open Keynotes podcast, Dr. Marcello Molle discusses different techniques for identifying the sentinel lymph node for patients with melanoma. This episode discusses the following PRS Global Open article: Comparison of Different Techniques for the Assessment of Sentinel Lymph Node Biopsy in Melanoma: A Systematic Review by Sara Izzo, Marcello Molle, Francesco Paolo Gesuete, Claudia De Intinis, Paolo Izzo, Luciano Izzo and Giovanni Francesco Nicoletti. Read the article for free on PRSGlobalOpen.com: https://bit.ly/LymphMelanoma Dr. Marcello Molle is a senior resident at the Universita degli studi della campania Luigi Vanvitelli in Naples, Italy. Your host, Dr. Damian Marucci, is a board-certified plastic surgeon and Associate Professor of Surgery at the University of Sydney in Australia. #PRSGlobalOpen #KeynotesPodcast #PlasticSurgery

A perennial topic on GU Cast!! But today we welcome a couple of very useful papers in European Urology Oncology which help us understand how PSMA PET/CT can help patient selection for pelvic lymph node dissection in prostate cancer. We are joined by Dr Giorgio Gandaglia from San Raffaele Hospital in Milano to discuss these two papers (links below). We also hear about Declan's recent trip to San Raffaele as Visiting Professor, and he sits down for a wide-ranging chat with professor Francesco Monitorsi, Director & Professor of Urology at San Raffaele. Even better on our YouTube channelLinks:Can PSMA reduce PLND? A systematic reviewOptimal use of PSMA to select patients for PLND. Updated validation of the Briganti and MSKCC nomograms

Welcome to the Sterile Technique Podcast! It's the podcast about Surgical Technology. Whether you are a CST or CSFA, this podcast helps you earn CE credits and improve your surgery skills in the OR. This episode discusses the cover article of the December 2023 issue of The Surgical Technologist, which is the official journal of the Association of Surgical Technologists (AST). The article is titled, "Preventing Surgical Site Infection After Inguinal Lymph Node Dissection". "Scrub in" at steriletpodcast.com and on Twitter, @SterileTPodcast (twitter.com/SterileTPodcast). This podcast is a Dybas Media production. Sound effects adapted from GarageBand and sindhu.tms at https://freesound.org/people/sindhu.tms/sounds/169065/ and licensed courtesy of https://creativecommons.org/licenses/by-nc/3.0/.

Ang Cui joins Immune to discuss her career and her work on establishing the Immune Dictionary, a compendium of single-cell transcriptomic profiles of more than 17 immune cell types in response to each of 86 cytokines (>1,400 cytokine-cell type combinations) in mouse lymph nodes in vivo. Hosts: Vincent Racaniello, Cynthia Leifer, and Brianne Barker Guest: Ang Cui Subscribe (free): Apple Podcasts, Google Podcasts. RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Publishing is broken (Solving for Science) Immune Dictionary (Nature) Time stamps by Jolene. Thanks! Music by Steve Neal. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv

Dr Ashish Kamat (MD Anderson Cancer Centre, Houston),  joins Declan and Renu to discuss a very nice paper recently published in European Urology Oncology overviewsing the role of lymph node dissection (LND) in GU oncology. Really nice piece of work led by Dr Amanda Myers along with a bunch of well known names in urologic oncology. A very succinct summary of LND in bladder, upper tract urothelial, renal, prostate, penile and testicular cancer. Check out the link below to find the full paperEven better on our YouTube channelLinksMyers et al paper 

Carla Nowosad joins Immune to discuss her career and her work on germinal centers, the structure in secondary lymphoid tissues where B cells proliferate, differentiate, and diversify their immunoglobulin genes by somatic hypermutation. Hosts: Stephanie Langel, Cynthia Leifer, and Brianne Barker Guest: Carla R. Nowosad Subscribe (free): Apple Podcasts, Google Podcasts. RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server B cells and the intestinal microbiome (Sem Immunol) B cell selection in gut germinal centres (Nature) B cell antigen internalization (Methods Mol Biol) Immune synapse architecture (Nat Immunol) Time stamps by Jolene. Thanks! Music by Steve Neal. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv

Breast cancers that are lymph node-positive are usually treated with chemotherapy before surgery (neoadjuvant chemotherapy). If those cancers become lymph node-negative after neoadjuvant chemotherapy, there's been a debate about whether to treat the nodes or not. A new study has practicing-changing results: Nodal radiation isn't need. Dr. Marisa Weiss, Breastcancer.org chief medical officer and founder, and radiation oncologist, explains the findings. Listen to the podcast to hear Dr. Weiss explain: why there has been debate about how to treat this type of breast cancer the study results what the results mean for patients

SABR supremos Piet Ost and Shankar Siva join us to discuss the management of lymph node-only recurrence following primary treatment of prostate cancer. And of course our resident PSMA PET/CT guru Michael Hofman also turned up as himself and Piet love debating the merits of PSMA!How and when shoudl we image for biochemical recurrence? What are the limits of SABR? WHat about systemic therapy? It's all in this episode with great leaders in the field.Recorded on site at Peter Mac on the fringe of the 2023 SABR Symposium. With your usual hosts Renu Eapen and Declan MurphyEven better on our YouTube channel 

Keep that lymph fluid flowing at Gentle Wellness Center! More details at https://www.mygentlewellness.com/ Gentle Wellness Center City: Fairfax Address: 12011 Lee Jackson Memorial Highway, STE 420 Website http://www.mygentlewellness.com Phone +1-703-996-3999 Email info@mygentlewellness.com

Immune reveals the total mass (1.2kg), number (1.8 trillion), and distribution of immune cells in the human body, with macrophages contributing nearly 50% of the total cellular mass. Hosts: Vincent Racaniello, Cynthia Leifer, and Brianne Barker Subscribe (free): Apple Podcasts, Google Podcasts. RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Immune cells in the human body (PNAS) Letters read on Immune 73 Time stamps by Jolene. Thanks! Music by Steve Neal. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv

Full article: https://ajronline.org/doi/10.2214/AJR.23.29984  Robbie Hill, MD discusses an article in which the authors derive an optimal size threshold for determining retropharyngeal lymph node involvement in nasopharyngeal carcinoma (NPC) based on outcome predictions. The authors show that the optimally derived threshold of 6mm provides better outcome predictions and may lead to improved treatment decision-making for patients with NPC.

Interview with Oreste Davide Gentilini, MD, author of Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. Hosted by Jack West, MD. Related Content: Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes

Interview with Oreste Davide Gentilini, MD, author of Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. Hosted by Jack West, MD. Related Content: Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes

Breast cancer is the most commonly diagnosed cancer worldwide, affecting over 2 million women each year. The most important predictor of both recurrence and survival in patients with breast cancer is if cancer has spread to the axillary lymph nodes.Dr. Alyssa Cubbison at The Ohio State University Wexner Medical Center specialises in breast imaging.  She puts forward an algorithm she helped create that uses preoperative ultrasound imaging of the axilla when facing suspected breast cancer.  Read the original research: 10.1016/j.clinimag.2022.04.011Dr. Cubbison can be contacted via Twitter or email

BEST OF HMS PODCASTS - THURSDAY - July 6, 2023 Learn more about your ad choices. Visit megaphone.fm/adchoices

BEST OF HMS PODCASTS - THURSDAY - July 6, 2023 Learn more about your ad choices. Visit megaphone.fm/adchoices

Kottie may just be the biggest worrywart OR she is a genius who discovered the next new strain of covid before any doctors. You can be the judge of that. 

Hosted by: Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic Oncology Featuring: Jennifer Mueller MD, Memorial Sloan Kettering Cancer Center Emad Matanes MD, Rambam Medical Center Emma Rossi MD, Duke University Medical Center Editor's Choice Papers: Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon? Is sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia? Editorial: Routine SLN biopsy for endometrial intraepithelial neoplasia: A pragmatic approach or over-treatment?

Editor's Choice Papers:  Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon? Is sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia? Editorial: Routine SLN biopsy for endometrial intraepithelial neoplasia: A pragmatic approach or over-treatment? Hosted by:Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic Oncology Featuring: Jennifer Mueller MD, Memorial Sloan Kettering Cancer CenterEmad Matanes MD, Rambam Medical CenterEmma Rossi MD, Duke University Medical Center    

Cindy, Steph, Brianne, and Vincent review some of their favorite immunology papers of 2022. Hosts: Vincent Racaniello, Cynthia Leifer, Steph Langel, and Brianne Barker Subscribe (free): Apple Podcasts, Google Podcasts. RSS, email Become a patron of Immune! Links for this episode CAR T for SLE (Nat MEd) Maternal gut microbiome induced IgG (Sci Immunol) Long-primed germinal centers (Nature) Fc mediated protection against SARS-CoV-2 VOC (bioRxiv) Dark side of macrophages (Nat Med) Pregnancy and antibody protection against infection (Nature) Regulators of inflammatory response to mRNA vaccines (Nature Immunol) Antibody effector function and protection against RSV (Cell) Color coded antibodies (bioRxiv) Endogenous retroviruses and inflammation (Cell) CD8 T cells and vaccine protection against SARS-CoV-2 (Sci Immunol) Time stamps by Jolene. Thanks! Music by Steve Neal. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv

Here's something interesting you should know about lymph nodes and your immune system. Dr. Berg's Keto and IF Lab: https://www.facebook.com/groups/drbergslab/ How to Bulletproof your Immune System FREE Course: https://bit.ly/39Ry3s2 FREE MINI-COURSE ➜ ➜ Take Dr. Berg's Free Keto Mini-Course! ADD YOUR SUCCESS STORY HERE: https://bit.ly/3z9TviS Find Your Body Type: https://www.drberg.com/body-type-quiz Talk to a Product Advisor to find the best product for you! Call 1-540-299-1557 with your questions about Dr. Berg's products. Product Advisors are available Monday through Friday 8 am - 6 pm and Saturday 9 am - 5 pm EST. At this time, we no longer offer Keto Consulting and our Product Advisors will only be advising on which product is best for you and advise on how to take them. Dr. Eric Berg DC Bio: Dr. Berg, 51 years of age is a chiropractor who specializes in weight loss through nutritional & natural methods. His private practice is located in Alexandria, Virginia. His clients include senior officials in the U.S. government & the Justice Department, ambassadors, medical doctors, high-level executives of prominent corporations, scientists, engineers, professors, and other clients from all walks of life. He is the author of The 7 Principles of Fat Burning. Dr. Berg's Website: http://bit.ly/37AV0fk Dr. Berg's Recipe Ideas: http://bit.ly/37FF6QR Dr. Berg's Reviews: http://bit.ly/3hkIvbb Dr. Berg's Shop: http://bit.ly/3mJcLxg Dr. Berg's Bio: http://bit.ly/3as2cfE Dr. Berg's Health Coach Training: http://bit.ly/3as2p2q Facebook: https://www.facebook.com/drericberg Messenger: https://www.messenger.com/t/drericberg Instagram: https://www.instagram.com/drericberg/ YouTube: http://bit.ly/37DXt8C Pinterest: https://www.pinterest.com/drericberg/

In this episode, Dr. Art Mollen walks through topics such as what to do about heel and hamstring pain, how to train for a marathon, what you can do to mitigate migraines, how love can positively affect your health, and more!     Head on over to SpeakPipe.com/AskDrArtMollen to record a voicemail to be featured on the show, or email AskDrArtMollen@gmail.com to have your question read aloud and answered!

Christopher Weight, MD, Center Director of Urologic Oncology at Cleveland Clinic joins the Cancer Advances podcast to discuss robot assisted retroperitoneal lymph node dissection (RPLND) for the treatment of testicular cancer. Listen as Dr. Weight explains how this robotic surgery allows shorter hospital stays, quicker recovery time, and a lower rate of chylous ascites.

Hosted by: S. Diane Yamada, MD, Deputy Editor of Gynecologic Oncology Featuring: Maaike Oonk, MD, University Medical Center Groningen, University of Groningen, The Netherlands Akila Viswanathan, MD, MPH, Johns Hopkins Medicine Editor's Choice Paper: Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe Editorial:When is it safe to omit contralateral groin management in unilateral sentinel node-positive early stage vulvar cancer?

In this episode of SurgOnc Today®,  Judy Boughey, MD, from the Mayo Clinic in Rochester, MN, and Vice Chair of the SSO Breast Disease Site Work Group, discusses with her colleagues how they manage a missing clipped axillary lymph node. She is joined by Puneet Singh, MD, from MD Anderson Cancer Center and Firas Eladoumikdachi, MD, from Rutgers Cancer Institute of New Jersey. Their discussion is focused on patients with node positive breast cancer who were treated with neoadjuvant chemotherapy.

Holmberg's Morning Sickness - Opening Break - Tuesday June 28, 2022

Holmberg's Morning Sickness - Opening Break - Tuesday June 28, 2022 Learn more about your ad choices. Visit megaphone.fm/adchoices

Meet long-time STRONG Girl and Toronto-based radio host Sandra Crofford, who takes us through her experience with thyroid cancer and how becoming a STRONG Girl enhanced and changed her life and wellness journey. In this episode, Jenny and Sandra talk about what symptoms to pay attention to, how the thyroid affects our whole body, and the importance of being an advocate for your own health when it comes to investigating those (or any other) unexplained symptoms. Sandra shares her incredible story and reminds us how crucial it is to be mindful, accountable and dedicated to being the best version of yourself. Follow Sandra on IG  JOIN The YOUR BEST BODY PRIVATE COMMUNITY and for the Password say "Jenny invited me"JOIN The YOUR BEST BODY PROGRAM   If you enjoyed this episode, make sure and give us a five star rating  and leave us a review on iTunes, Podcast Addict, Podchaser and Castbox. STRONG Fitness Magazine Subscription Use discount code STRONGGIRLResourcesSTRONG Fitness MagazineSTRONG Fitness Magazine on IGTeam Strong GirlsCoach JVBFollow Jenny on social mediaInstagramFacebookYouTube   

In pharmacology, getting your drug to where it's needed is everything. In immunology, to elicit an immune response that location is often the lymph node, and the point of delivery are antigen presenting cells. Amphiphile, from Elicio, can make that happen. Whether the cargo is DNA, a peptide, or a small molecule, once linked to the Amphiphile moiety, the construct is taken up by the lymphatic system. First asset in the clinic? A multiple antigen therapeutic for mKRAS.

Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks… Kayla: Hi, I am working with an integrative practitioner right now. I have had a sharp pain in my lower left stomach, which she said it was a swollen lymph node. My candida antibodies came back extremely high, so I am currently taking antifungal herbs, as well as a probiotic and it my pain and symptoms seem to be getting worse. Do you think there are other underlying problems contributing to this pain? Or why do you think there is such a sharp pain in the lower left abdomen? Thank you so much!   Jenny: Hi Dr. Cabral - I am a long-time, dedicated podcast listener and am so appreciative of the information and insights you share. I am excited to now be a Ayubowan Member and look forward to receiving on going lab tests and coaching calls along with it. I follow the foundational protocol level 2 daily and also take your immune support products. My question has to do with the new longevity line of products that I am also excited to try. Because some of them include some of the supplements I'm already taking daily, how can I determine whether I should continue with my current supplements in addition to the longevity products? I have been reluctant to order the ones I'm most interested in trying because I am unsure. Much thanks to you and your amazing team!   Hans: how to rid the body of a fatty liver   Mally: Hi Dr. Cabral! Thank you so much for all you do, your podcasts and Equilife products have been SUCH a blessing for me and my family! I have ran a stool & organic acids test test through my local functional doctor, and have completed a 6 month bacteria overgrowth protocol through him. I recently tested for incredibly high levels of Ochratoxin A and started on your mold protocol. (His protocol called from some intense binders, so I did not feel comfortable taking those while my body is already herxing.) I appreciate how your mold protocol has less side effects. My question is, is your protocol able to address mold that has colonized in the sinuses and/or organs? My chronic sinusitis started when I was a kid and I am wondering what the proper expectation should be are far as recovery time. I have seen decent amounts of biofilm in my stool for about 6 months now. Also, is there any bloodwork I should be monitoring while I am detoxing so heavily?   Crystal: Hi Dr. Cabral! Because of my PCOS, I now have chronic dry eye syndrome. I have listened to all of your podcasts on dry eye that I could find and nothing seems to help. The only thing that has seemed to help the constant burning are Restasis eye drops that my eye doctor prescribed me. The dry eye suddenly started in Feb. 2020 out of nowhere and ever since, my eyes are really red and a large, visible, red vein has formed in my right eye. My eye doctor told me it will never go away, but I just don't want to believe that. My eyes have always been my best feature and I hate having red eyes all of the time and this giant red vein. What can I do to stop my dry eye and can I ever get rid of the red vein? Sorry my question is so long, but I so appreciate you taking your time out to answer my question and I value your work and advice so much. Thank you Dr. Cabral, you are my biggest inspiration!   Michael: Hi Dr Cabral what would cause someone to burp omega 3 capsules? I've tried many functional medicine brands but I keep burping them. I have low stomach acid, tested positive for h pylori and I probably have sibo as well. Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes & Resources:  http://StephenCabral.com/2270 - - - Dr. Cabral's New Book, The Rain Barrel Effect https://amzn.to/2H0W7Ge - - - Join the Community & Get Your Questions Answered: http://CabralSupportGroup.com - - -  Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Stress, Sleep & Hormones Test (Run your adrenal & hormone levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels)

GU Cast is back after our summer break in Melbourne, with a cracking episode focussing on pelvic lymph node dissection in prostate cancer. Pelvic lymph node dissection (PLND) is a perennially contentious topic in urology, and we were delighted today to welcome Dr Karim Touijer, Attending Surgeon at Memorial Sloan Kettering in New York, to discuss the randomised controlled trial which he and his colleagues published recently. This paper was highlighted as "Paper of the Year" by European Urology Oncology - congratulations to Dr Touijer and colleagues! A huge trial, with about 1500 men being randomised to undergo limited or extended PLND, to determine if a more extended dissection improved biochemical recurrence-free survival. We were also delighted to welcome Dr Wouter "Wally" Everaerts to discuss this topic. Wally is Consultant Urologist and Program Director at KU Leuven, one of Europe's top prostate cancer centres, with huge expertise in PLND. Wally is a Melbourne alumnus and it was great have him on GU Cast. We enjoyed talking surgery in depth today - more surgically oriented discussions coming this year!Watch the Youtube version here Links:Eur Urol Oncol paper Dr Karim Touijer TwitterDr Wouter Everaerts Twitter

Gabriel Victora joins Immune to review how high affinity antibodies are produced in the germinal centers of secondary lymphoid tissues. Hosts: Vincent Racaniello, Stephanie Langel, Cynthia Leifer, and Brianne Barker Guest: Gabriel Victora Subscribe (free): Apple Podcasts, Google Podcasts. RSS, email Become a patron of Immune! Links for this episode Concerto in B (TWiV 161) Visualizing antibody affinity maturation (Science) Restricted B cell clonality after boosting (Cell) Time stamps by Jolene. Thanks! Music by Steve Neal. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv

Please fill out the survey! https://forms.gle/xRWFksZkgodAa3hE8 Ally and Ned (mostly Ally - this was way over Ned's head) talk about Pelvic Lymph Node Dissections. Intro (0:15), Anatomy (3:39), Surgical Methods (8:57), Surgical Snippets (15:36)

Dr. Martha Terris MD discusses the role of salvage lymph node dissection for recurrent prostate cancer 5/4/20

It is often a scary and stressful time when you are first diagnosed with a parotid tumor. There is nobody who understands how you feel better than your Host, Heidi Semann; a fellow parotid patient who has been through this process.Patients are overwhelmed by information and medical terms that they often don't understand, which makes this process even more difficult.One of the things that helped Heidi get through this process was being provided current, trusted, and accurate information by her surgeon, Dr. Eric J. Moore, Chair, Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota.In this episode, Dr. Moore joins Heidi to discuss parotid tumor basics; what to expect when you are newly diagnosed; how to select a surgeon; and COVID-19 considerations when receiving medical care.Listen in to this informative episode.Key Talking Points of the Episode:·        Understanding the medical terms ·        Understanding differences between a parotid mass, lesion, cyst, tumor,           and lymph node ·        Common symptoms of a parotid tumor·        Diagnostic tests·        Tips for selecting a surgeon·        Telehealth consultations·        COVID-19 considerations and patient appointmentsMemorable Quotes from the Episode:“I want you to remember this, it is going to be okay. Even if it does not feel that way right now.”“A tumor is attached to a living human being, and that's going to influence the disease course a lot.”“At the end of the day, trust your parotid tumor to someone who really concentrates in parotid gland treatment because it is not a real common disease.”“The physician patient contract is founded on the principle that there's trust. And also there's a like vision with shared information.”“The medical institutions are extremely cautious and thoughtful about transmission of COVID-19.”Connect with Us:·        Parotid Patient Project·        Facebook·        Instagram·        Twitter·        Email: podcast@parotidpatientproject.org Don't forget to like and subscribe to the podcast to stay fully up to date!  As always, know that you are not alone in this journey. 

Blaine recently discovered something that needed a look from the good ol' doc. In this mid-week, bonus episode, we talk about what it feels like to wait (yes, more waiting) for some possibly unsettling results, as we learn from poet David Whyte on the power of vulnerability in moments like these.

On this episode of the SO Files, Brad and Linda discuss the current state and future of surgical lymph node management. The SO Files welcome special guest, Dr. William Hawkins, Neidorff Family and Robert C. Packman Professor of Surgery and Chief, Section of Hepatobiliary-Pancreatic and Gastrointestinal Surgery at the Washington University School of Medicine/ Siteman Cancer Center. We hope you enjoy this interesting discussion!